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BY-NC-ND license (http://creativecomBackground: Fear of cancer recurrence (FCR) is one of the most distressing concerns for cancer
patients. A psychometrically validated brief scale is urgently needed for use in busy clinical
oncology settings. This study aimed to (1) develop and validate the 7-item fear of cancer recur-
rence scale Chinese version (FCR7-C), and (2) explore the severity of FCR in post-operative
early-stage lung cancer patients in Taiwan.
Methods: Early-stage lung cancer patients were recruited from a medical center in Taiwan.
The FCR7-C was evaluated for content and construct validity and internal consistency reli-
ability. Construct validity of FCR7-C was determined by the empirically supported correlation
and confirmatory factor analysis (CFA).
Results: A total of 160 subjects were recruited. The FCR7-C was shown to have satisfactory
content validity and internal consistency reliability (Cronbach’s a Z 0.9). The uni-
dimensional structure was confirmed by CFA that showed a good fit for the model. The
FCR7-C score correlates positively with the degree of most of the physical symptoms, anxiety,
and depression, but correlates negatively with patient age, performance status, and quality of
life. We found that 81.9% of patients reported at least some FCR, with a mean FCR severity of
15.18 (SD Z 7.78).rsing, National Taiwan University Cancer Center, College of Medicine, National Taiwan University, 1
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1102 Y.-H. Lee et al.Conclusion: FCR7-C is a brief screening tool with good psychometrics. Patients with early-stage
lung cancer still revealed mild to moderate level of FCR. Applying the FCR7-C for to screen
cancer patients’ distress and further develop personalized psychological interventions would
be strongly suggested.
Copyright ª 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Fear of Cancer Recurrence (FCR) is defined as the
emotional distress caused by the concern that cancer will
return or progress after anti-cancer treatment. FCR is
prevalent among cancer survivors.1,2 Generally, severity of
FCR is also known as level of patients’ FCR experience.
Severe FCR can interfere with a patient’s ability to move
forward with their life and to plan for the future.3,4 Pa-
tients with severe FCR may experience sleep disturbances,5
anxiety and depression,6e9 and poor quality of life
(QOL)10e12 and may require more health care services.13
Thus, the assessment of FCR in cancer survivors is impor-
tant. However, relatively few assessment tools have been
developed to be used in Chinese population, such as in
Taiwan, China, Hong Kong, and across the world. Thus,
there is limited information about the severity of Chinese
cancer patients’ concerns about disease recurrence.
Numerous FCR assessments have been developed over
the past decade.14 For example, the comprehensive 42-
item multidimensional Fear of Cancer Recurrence In-
ventory covers multiple domains of FCR in detail8 and has
been widely used to assess FCR in cancer patients15 and
their caregivers.16 However, given the burden on patients
by repeated assessments during cancer follow-up and the
time constraints in the clinical setting, a brief yet accurate
scale would better serve patients and clinicians.
The 7-item unidimensional Fear of Cancer Recurrence
(FCR7) assessment was originally named the ‘Fear of
Recurrence’.6 The FCR7 has been used to assess FCR in head
and neck cancer patients. The FCR7 consists of 4 items to
assess the level of worry about cancer recurrence, 2 items
that measure the level of interference of FCR with the
patient’s thoughts and activities, and 1 item to assess the
patient’s behavioral response.6,17 The overall scale repre-
sents the experiences of the level (severity) of patients’
FCR.
To evaluate the psychometric properties of the FCR7,
the construct validity has been examined by determining
whether the assessment took into account the factors
known to affect FCR severity.1,10,18e20 For example, more
severe FCR tends to occur in younger patients1,18 and in
those with poor physical status.1 More severe FCR is also
closely linked to higher anxiety and depression.18,19 Phys-
ical symptoms may increase the FCR by reminding patients
about their physical status and the possibility of cancer
recurrence.20e22 Patients with more severe FCR report a
lower quality of life.10
Together, based on the evidence presented above, the
following predictions regarding correlations between theChinese version of FCR7 (FCR7-C) score and related pa-
rameters were made: (1) The FCR7-C score will correlate
positively with cancer-related symptoms (pain, fatigue,
nausea/vomiting, dyspnea, insomnia, lack of appetite,
constipation, and diarrhea), depression, and anxiety; and
(2) The FCR7-C score will correlate negatively with patient
age, performance status, and overall QOL. In addition, the
FCR7-C should reflect the uni-dimensional design of the
original FCR7.17
We chose early-stage lung cancer patients to assess the
effectiveness of FCR7-C because FCRmay be common among
patients with lung cancer due to its highmortality.23 Previous
studies report a high prevalence of FCR (72%) among patients
with lung cancer24 and more severe FCR in patients with lung
cancer than with other types of cancer.8 Although screening
methods for earlier detection of lung cancer25 have improved
the 5-year survival rate of early-stage lung cancer (40e70%)
in Taiwan,26,27 the reputation of lung cancer as a deadly
disease may induce particular fear.
To establish an effective assessment for FCR in Chinese-
speaking cancer patients, this study aimed to (1) translate
and develop the FCR-7 into Chinese (step I), and (2)
examine the psychometrics of the FCR7-C and explore the
severity of FCR in operable early-stage lung cancer patients
(step II).Methods
Step 1: Translation, development and examination
of content validity
After obtaining permission from the original authors to use
the FCR76, the instrument was translated into Chinese and
the accuracy of Chinese translation was confirmed by back-
translating between English and Chinese based on the in-
strument translation principles.28 The content validity of
FCR7-C was examined and discussed by 5 experts (2 on-
cologists, 2 psycho-oncology nurse researchers, and one
master-prepared oncology nurse), who found that FCR7-C is
satisfactory.
For face validity (from patients), we recruited 10 lung
cancer patients from the thoracic surgery outpatient clinic
in a medical center in Northern Taiwan. Eligible subjects
were adult patients who (i) were diagnosed with early-
stage lung cancer (stages I, II, & IIIA), (ii) had undergone
tumor resection surgery, (iii) were currently disease-free,
and (iv) were able to communicate in Chinese or Taiwa-
nese. IRB approval (IRB number: 201012108RC) and pa-
tients’ consents were obtained before data collection.
Screening for fear of cancer recurrence instrument 1103All of the 10 patients reported that the FCR7-C reflected
their fears of cancer recurrence and that it was easy to
understand and answer. Thus, the face validity of FCR7-C
was well supported by the patients.
Step II: Examination of the reliability and construct
validity of the FCR7-C
In step II, the same recruitment criterion and settings were
applied. We assessed the internal consistency reliability
using the calculated Cronbach’s alpha value. Construct
validity was examined in 2 ways: (1) testing the correlation
between assumptions and actual outcomes with respect to
FCR7-C variables, and (2) conducting confirmatory factor
analysis (CFA) to verify the dimensionality of the FCR7-C.
The goal of using CFA, rather than using exploratory factor
analysis (EFA), is that “CFA model is specified in advance
and being evaluated by goodness of fit and the interpret-
ability and strength of the parameters”.29 Thus, in this
study, we applied CFA to verify the FCR7-C as its assumed
one-factor structure (uni-dimensional scale). Finally, after
the validation, results of the severity of cancer recurrence
would be also explored from the step II results in FCR7-C.
Measures
To compare theoretical and actual outcomes of the FCR7-C
for selected variables, we used several tools, including the
Karnofsky performance status (KPS),30 2 overall QOL items
and the Symptom Subscale from the European Organization
for Research and Treatment of Cancer QOL Questionnaire
(version 3.0) (EORTC QLQ-30),31 and the Hospital Anxiety
and Depression Scale (HADS).32
Fear of Recurrence 7 (FCR7)
The original FCR7 questionnaire consists of 7 questions. The
first 6 of these questions are scored on a 5-point scale. The
scoring system is: ‘1 Z not at all’, ‘2 Z a little’,
‘3Z sometimes’, ‘4Z a lot’ and ‘5Z all the time’. The 7th
item is used to assess the extent to which FCR interferes with
thepatient’s thoughtsandactivities and is scoredona10-point
scale,with ‘0’ indicating ‘notat all’ and ‘10’ indicating ‘agreat
deal.’ For each individual item, a score4 on questions 1 to 6
(ranging from1 to5), or7 onquestion 7 (ranging from0 to10)
indicates a significant level (severity) of fear of cancer recur-
rence6 and suggests that the patient needs further help.6
Although there is no definite cut-off point to decide pa-
tients’ FCR, the single item or total (sum) scores can be all
used for preliminarily identifying patients’ severity of FCR as
the above scoring suggestion. The total score is ranged from
6 to 40, with higher the score indicating higher level of FCR.
Karnofsky performance scale (KPS)
The Karnofsky performance scale (KPS) was used to assess
patients’ ability to perform tasks of daily living. The
possible score on this 11-item assessment ranges from 100
(fully normal function) to 0 (death).30
EORTC QLQ-30
Twooverall QOL questions and the symptomsubscale from the
EORTC QLQ-C30 were incorporated into this assessment. Thesymptom subscale includes fatigue, pain, nausea, dyspnea,
insomnia, lack of appetite, constipation, anddiarrhea, eachof
which was rated using a 4-point Likert Scale (1, not at all; 4,
verymuch). The original scores are then transformed to a 100-
point scale score, with a higher score indicating better QOL.31
The Taiwan Chinese version of the EORTC QLQ-C30 for lung
cancer patients has beenproven tobe reliable and valid.33 The
Cronbach’s alpha in this study was 0.91 for the overall EORTC
QLQ-C30 symptom scale and 0.67e0.79 for each symptom.
Hospital Anxiety and Depression Scale (HADS)
Patient anxiety and depression levels were assessed using
the HADS scale,32 which consists of two subscales: anxiety
and depression, and contains 7 items per subscale, with a
maximum subscale score of 21 per subscale. A higher score
indicates a higher level of anxiety or depression. Satisfac-
tory psychometrics for the HADS has been reported in
cancer-related studies in Taiwan.34 In this study, the
Cronbach’s alpha for the anxiety and depression subscales
was 0.83 and 0.70, respectively.
Background information form
Background information obtained included the patients’
gender, age, education, marital status, religion, occupation,
cancer stage, type of surgery, and time since diagnosis.Statistical analysis
Internal consistency reliability was indicated by Cronbach’s
alpha coefficient. Construct validity was examined by confir-
matory factor analysis to confirmtheuni-dimensionality of the
design. The CFA was examined using the Analysis of Moment
Structure (AMOS), version20. The goodness of fit for themodel
was evaluated by chi-square analysis (c2), the ratio of chi
square to degrees of freedom (c2/df), and other commonly
used indicators, including the root mean square of error
approximation (RMSEA), standardized root mean-square re-
sidual (SRMR), normed-fit index (NFI), relative fit index (RFI),
goodness of fit index (GFI), and relative fit index (RFI). The
recommended cut-offs that indicate a good fit for RMSEA
<0.08, SRMR<0.08, NFIS0.95, GFIS0.95, RFIS0.95.35 The
modification index (MI) was used to determine the error cor-
relations on parameter estimates of CFA if needed.36
Spearman’s analysis of empirically supported correla-
tions between FCR7-C and selected variables were exam-
ined for support of the construct validity. Variables
investigated for correlation with FCR include patient age,18
physical status,1 severity of symptoms,5,12,20 and level of
psychological distress.6,7,9,37 Finally, the FCR severity in
early-stage lung cancer patients was determined by sta-
tistical analysis of the data.
The sample size was determined based several con-
cerns.38 These included (1) the effect of factors; (2) the
effect of number of indicators; (3) effect of magnitude of
factor loadings; and (4) the effect of magnitude of factor
correlations. For example, the six-to eight-indicator, one
factor model and loading 0.50 were associated with a
minimum sample size of 90. The CFA in the current study,
one factor model with seven indicators, and all the factor
loading higher than 0.5 (ranging from 0.60 to 0.97) except
one (0.40) suggest the sample size as 160 is enough.
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Patient characteristics
In step II, a total of 160 subjects were recruited for psycho-
metric testing of FCR7-C and better representativeness for
the severity of FCR in early-stage lung cancer patients. There
were 87 females (54.4%) and 73 males (45.6%) and with a
mean age of 61.5 years (SD, 11.9). The demographic data are
presented in Table 1. Themajority of thepatients (83.1%) had
a good performance status with KPS score (90) (Table 1).Table 1 Background information of subjects (N Z 160).
n % Mean (SD) Range
Sex
Male 73 45.6
Female 87 54.4
Age (years) 61.5 (11.9) 30e87
Education level (years) 11.2 (5.1) 0e26
Illiterate 3 1.9
Elementary school 46 28.7
High school 49 30.5
College and above 62 38.9
Marital status
Unmarried, divorced,
widowed
23 14.4
Married 137 85.6
Religion
Yes 127 79.4
None 33 20.6
Occupational status
Employed 51 31.9
Unemployed 77 48.1
Unemployed since
having cancer
32 20.0
Cancer stage
I 123 76.8
II 14 8.8
IIIA 23 14.4
Surgery type
Lobectomy 129 80.6
Lobectomy þ Wedge
resection
15 9.4
Wedge resection 13 8.1
Sleeve resection 2 1.3
Sleeve resection
þ Lobectomy
1 0.6
Time since diagnosis
(months)
8.9 (4.6) 3e19
3e6 66 41.2
7e12 60 37.5
>12 34 21.3
Karnofsky performance
score
60 2 1.3
70 4 2.5
80 21 13.1
90 78 48.7
100 55 34.4The overall quality of life score (based on the EORTC
QLQ-C30, the two overall items mean score in a 0e100
system) for this cohort was 66.8 (SD Z 20.1). Patients
generally reported to have low symptoms, with the top
ranked symptom as dyspnea, sleep impairment and fatigue
and mean scores as 24.2, 23.5, and 21.0, respectively.
Reliability
The Cronbach’s alpha value for internal consistency reli-
ability in the current study was 0.90 for the FCR7-C. In order
to better know the item-quality of FCR7-C, we also examined
item to total (scale) correlation. The generally suggested and
acceptable item to total correlation values are 0.2, 0.3 or
0.4.39 In our study, except item 6, the item to total correla-
tion values were ranging from 0.72 to 0.85. Even for item 6, it
had item to total correlation as 0.45 which met the criteria.
We thus kept all the original items of FCR7. Taking together,
the result of Cronbach’s alpha as 0.9 and high item to total
correlation strongly support that FCR7-C has a very good in-
ternal consistency reliability40 (Table 2).
Construct validity
The standardized coefficients for items 1 through 7 ranged
from 0.42 to 0.97 (Fig. 1). Since the goodness of fit of the
model is not perfect, the MI was further applied to adjust
the model. Chi-square value (c2 Z 85.98; p < 0.001) were
found to be significant. The normed chi-square (c2/df) valueTable 2 Internal consistency reliability and item to total
correlations (N Z 160).
FCR items Item to Total
Correlation
Alpha if
Item Deleted
Q1 I am afraid that my
cancer may recur
0.85 0.87
Q2 I am worried or anxious
about the possibility of
cancer recurrence
0.86 0.87
Q3 How often have you
worried about the
possibility of getting
cancer again?
0.84 0.87
Q4 I get waves of strong
feelings about the
cancer coming back
0.72 0.89
Q5 I think about the cancer
returning when I did not
mean to
0.81 0.88
Q6 I examine myself to see
if I have physical signs of
cancer
0.45 0.91
Q7 To what extent does
worry about getting
cancer again spill over or
intrude on your thoughts
and activities
0.76 0.91
Note: Overall Cronbach’s alpha Z 0.90.
Figure 1 Results of confirmatory factor analysis of the FCR7-C.
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RMSEA index was 0.09, indicating a mediocre fit. Additional
indices, including the SRMR (0.04), NFI (0.97), RFI (0.95),
and the GFI (0.95), support a good fit. Overall, these indices
support the FCR7-C as a uni-dimensional model.
The results of Spearman’s correlation generally support
our assumptions (Table 3). The FCR7-C score had a low to
moderate negative correlation with age, physical function,
and QOL (r Z 0.33, 0.31, and 0.30, respectively). A
low positive correlation was observed for all individual
symptoms except constipation. The FCR7-C score corre-
lated positively with anxiety (high correlation; r Z 0.62)
and depression (moderate correlation; r Z 0.38) (Table 3).FCR severity
The total FCR severity score was 15.2 (SD Z 7.8), indicating
that these patients had mild FCR. No FCR was reported byTable 3 Correlation between FCR7-C and selected vari-
ables (N Z 160).
Selected Variables FCR7-C Total Score
Age 0.33*
Performance Status 0.31*
Overall QOL 0.30**
Generalized Symptoms
Pain 0.20**
Fatigue 0.43**
Nausea/vomiting 0.19*
Dyspnea 0.22**
Insomnia 0.29*
Lack of appetite 0.23**
Constipation 0.08
Diarrhea 0.21**
Anxiety 0.62**
Depression 0.38**
Data analysis: Spearman’s correlation; *p < 0.05, **p < 0.01.18.1% of patients across all 7 items, while the fraction of pa-
tients reporting significant FCR for items 1e7 was 19.4%,
18.8%, 19.4%, 6.3%, 11.9%, 20.6%, and 6.9%, respectively
(Table 4).Discussion
In our cohort of 160 subjects, the FCR7-C was shown to have
satisfactory content validity and internal consistency reli-
ability. The uni-dimensional structure was supported by
CFA that showed a good fit for the model. Consistent with
our hypothesis, the FCR7-C score correlates positively with
the degree of physical symptoms, anxiety, and depression,
but correlates negatively with patient age, performance
status, and QOL. We found that 81.9% of patients reported
at least some FCR, with a mean FCR severity of 15.18.
Several important issues were clarified by this study.
First, the satisfied internal consistency reliability of FCR7-C
was supported by the high Cronbach’s alpha of 0.90, which
is comparable to that of the original FCR7 assessment.6 All
items except number 6 demonstrated high individual to
total scale correlations (Cronbach’s aZ 0.72e0.86). Item 6
had a moderate correlation (Cronbach’s a Z 0.45).
Second, the results of CFA are generally acceptable to
confirm the uni-dimensional structure of the FCR7-C,
matching that of the FCR717 in a population of early-stage
lung cancer patients. Although the good of fitness model
was not perfect, the results after adjustment by MI
suggest that the FCR7-C is acceptable. The potential reason
for this lower fit is that item 6 has a relatively low item to
total correlation. The content of item 6 is less similar than
the other items in directly assessing the level of fear of
cancer recurrence. Rather, it assesses awareness of phys-
ical signs of recurrence, thereby only indirectly addressing
psychological concerns. Since the awareness of physical
signs of recurrence is a component of the construct of fear
of cancer recurrence, the final CFA model is generally
acceptable after adjustment. Thus, we accept the notion
that FCR7-C has a uni-dimensional structure.
All of the empirically based hypothesized assumptions
were fully supported by our data, which are consistent with
the findings of previous studies,1,5e7,9,12,18,20,37 except that
no significant correlation was observed between FCR
severity and constipation. It might be because of con-
stipation is not a major sign of lung cancer or its recur-
rence, this symptom may be less correlated to early-stage
lung cancer patients. However, the other GI symptoms,
diarrhea, has positive correlation with FCR. The possible
reason might be that diarrhea is generally a symptom to
reflect patients’ anxiety. FCR might induce patients’ anxi-
ety and thus it is related to patients’ diarrhea. More studies
need to be explored to better understand the phenomena.
Similar as previous study, fatigue has the highest correla-
tion to FCR.41 It supports that fatigue is the most robust
symptom in triggering a patient’s awareness of cancer
recurrence.
Finally, for early-stage operable lung cancer patients,
although not all patients reported concerns, 81.9% reported
at least “a little” FCR. Furthermore, for each individual
FCR7-C item, 6.3e20.6% of patients reported a significant
level of fear of cancer recurrence. One-fifth of the subjects
Table 4 Severity of fear of cancer recurrence (N Z 160).
FCR7
Questionnaire
Not at all
n (%)
A little
n (%)
Sometimes
n (%)
A lot
n (%)
All the time
n (%)
Significant
FCR (%) 4e5
1 2 3 4 5
Q1 I am afraid that my
cancer my recur
46 (28.7) 30 (18.8) 53 (33.1) 19 (11.9) 12 (7.5) 19.4
Q2 I am worried or
anxious about the
possibility of
cancer recurrence
47 (29.4) 37 (23.1) 46 (28.7) 18 (11.3) 12 (7.5) 18.8
Q3 How often have
you worried about
the possibility of
getting cancer
again?
47 (29.4) 47 (29.4) 35 (21.8) 19 (11.9) 12 (7.5) 19.4
Q4 I get waves of
strong feelings
about the cancer
coming back
97 (60.5) 38 (23.8) 15 (9.4) 7 (4.4) 3 (1.9) 6.3
Q5 I think about the
cancer returning
when I did not
mean to
57 (35.5) 50 (31.3) 34 (21.3) 13 (8.1) 6 (3.8) 11.9
Q6 I examine myself
to see if I have
physical signs of
cancer
60 (37.5) 36 (22.5) 31 (19.4) 24 (15.0) 9 (5.6) 20.6
Not at all A great
deal
Significant FCR
(%) 7e10
Q7 To what extent does worry
about getting cancer
again spill over or intrude on
your thoughts and activities
0 1 2 3 4 5 6 7 8 9 10
79 18 15 13 6 16 2 6 4 0 1
(49.3) (11.2) (9.4) (8.1) (3.8) (10.0) (1.3) (3.8) (2.5) (0.0) (0.6) 6.9
FCR-C (0e40) Mean (SD)
15.2 (7.8)
1106 Y.-H. Lee et al.(20.6%) experienced a significant level of FCR in their
response to item 6 (I examine myself to see if I have
physical signs of cancer). These results strongly suggest
that FCR is still an issue for early-stage lung cancer pa-
tients, indicating that screening for FCR among these is
needed to provide further interventions to decrease patient
distress and the number of outpatient department and
emergency room visits.13
Conclusions
This study is the first study to develop and examine the
Chinese version of FCR7 in early-stage lung cancer pa-
tients. The results strongly indicate that the FCR7-C is a
very brief, easily used, and psychometrically valid tool.
This assessment can be used to evaluate the severity of
FCR in early-stage lung cancer patients, even in very
busy outpatient care settings. Thus, we strongly recom-
mend the systematic use of the FCR7-C as a screening
tool for cancer patients in Chinese speaking patients as a
basis for providing personalized psychological
interventions.Study limitations
Although this study indicates that the FCR7-C is a psycho-
metrically valid tool, it still has some limitations. First, this
study only includes cross-sectional data. Further study is
needed to examine the test-retest reliability of FCR7-C.
Second, majority of subjects in this study are diagnosed as
lung cancer from health screening. Thus, we did not
compare the differences among stages (I-IIIa) due to limited
subjects in stage II and IIIa. Lack of sufficient subjects in
each group might limit the power of statistical analysis and
decrease the accuracy of results. Finally, the applicability
of the FCR7-C to different cancer populations must be
established.Clinical implications
Our results suggest that FCR7-C is a brief assessment to use
for screening cancer patients for FCR in clinical settings in
Taiwan. Integrating the brief FCR7-C into hospital infor-
mation system to screen patients’ FCR is strongly
Screening for fear of cancer recurrence instrument 1107suggested. We also suggest to integrate the assessment into
cancer care case management system. Thus, health care
professionals can provide more personalized interventions
to support those with high fear of cancer recurrence.
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